Based on real-world data, Johnson & Johnson (NYSE:JNJ) announced Wednesday its prostate cancer therapy Erleada (apalutamide) ...

almost all patients progress to castration-resistant prostate cancer (CRPC). The understanding of the biology of CRPC and the evidence that CRPC still remains driven by androgen receptor signaling ...

Results from the phase 3 PEACE-3 study found that a combination therapy showed higher benefits for patients with bone ...

Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...

Explore our latest breakthroughs in metastatic prostate cancer research. Learn more about our innovative pipeline today! @ ...

Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...

The medicine is approved for prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway ...

Bayer announced the submission of an application to the European Medicines Agency for the oral androgen receptor inhibitor ...

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase ...